Sadahiro Naka, Kazuhiro Ooe, Yoshifumi Shirakami, Kenta Kurimoto, Toshihiro Sakai, Kazuhiro Takahashi, Atsushi Toyoshima, Yang Wang, Hiromitsu Haba, Hiroki Kato, et al. Production of [211At]NaAt solution under GMP compliance for investigator-initiated clinical trial. EJNMMI radiopharmacy and chemistry. 2024. 9. 1. 29-29
Yuta Kaizuka, Hiroyuki Suzuki, Tadashi Watabe, Kazuhiro Ooe, Atsushi Toyoshima, Kazuhiro Takahashi, Koichi Sawada, Takashi Iimori, Yoshitada Masuda, Takashi Uno, et al. Neopentyl glycol-based radiohalogen-labeled amino acid derivatives for cancer radiotheranostics. EJNMMI radiopharmacy and chemistry. 2024. 9. 1. 17-17
Kazuko Kaneda-Nakashima, Yoshifumi Shirakami, Yuichiro Kadonaga, Tadashi Watabe, Kazuhiro Ooe, Xiaojie Yin, Hiromitsu Haba, Kenji Shirasaki, Hidetoshi Kikunaga, Kazuaki Tsukada, et al. Comparison of Nuclear Medicine Therapeutics Targeting PSMA among Alpha-Emitting Nuclides. International Journal of Molecular Sciences. 2024. 25. 2. 933-933
Atsushi Yagishita, Miho Katsuragawa, Shin’ichiro Takeda, Yoshifumi Shirakami, Kazuhiro Ooe, Atsushi Toyoshima, Tadayuki Takahashi, Tadashi Watabe. Development and Utility of an Imaging System for Internal Dosimetry of Astatine-211 in Mice. Bioengineering. 2023. 11. 1. 25-25
Tadashi Watabe, Kazuya Kabayama, Sadahiro Naka, Ryuku Yamamoto, Kazuko Kaneda, Satoshi Serada, Kazuhiro Ooe, Atsushi Toyoshima, Yang Wang, Hiromitsu Haba, et al. Immuno-PET and Targeted α-Therapy Using Anti-Glypican-1 Antibody Labeled with89Zr or211At: A Theranostic Approach for Pancreatic Ductal Adenocarcinoma. Journal of Nuclear Medicine. 2023. jnumed.123.266313-jnumed.123.266313